— Know what they know.
Not Investment Advice

PANC OTC

Panacos Pharmaceuticals, Inc.
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +0.0% 1Y: +0.0% 3Y: -90.0% 5Y: -82.8%
$0.00
+0.00 (+0.00%)
 
OTC · Healthcare · Biotechnology · Tech Score Neutral · Power 48 · $5367 mcap · 54M float · 0.0003% daily turnover

Balance Sheet Trends

Total Assets
$56M -15.1% ▼
5Y CAGR: +19.6%
Total Liabilities
$27M +285.1% ▲
5Y CAGR: +22.1%
Shareholders Equity
$29M -50.8% ▼
5Y CAGR: +17.6%
Cash & Investments
$52M -14.6% ▼
5Y CAGR: +48.2%
Total Debt
$19M +5249.3% ▲
5Y CAGR: +161.6%
Net Debt
-$19M +43.4% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2003FY2004FY2005FY2006FY2007
— Assets —
Cash$4M$5M$87M$33M$38M
Short-Term Investments$0$0$0$28M$14M
Cash & ST Investments$4M$5M$87M$61M$52M
Net Receivables$4M$280K$389K$66K$147K
Inventory$0$0$0$0$0
Other Current Assets$169K$0$0$0$0
Total Current Assets$9M$5M$89M$63M$53M
Property, Plant & Equip.$3M$310K$2M$2M$1M
Goodwill & Intangibles$3M$398K$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$2M$402K$605K$554K$2M
Total Non-Current Assets$8M$1M$3M$3M$3M
Total Assets$18M$6M$92M$66M$56M
— Liabilities —
Accounts Payable$915K$3M$2M$3M$3M
Short-Term Debt$0$129K$213K$361K$3M
Deferred Revenue$153K$0$0$0$0
Other Current Liabilities$1M-$1M$0$0$0
Total Current Liabilities$3M$3M$6M$7M$10M
Long-Term Debt$0$30K$0$0$16M
Other Non-Current Liab.$2M$30M$150K$459K$601K
Total Non-Current Liabilities$3M$30M$150K$459K$17M
Total Liabilities$5M$33M$6M$7M$27M
— Equity —
Common Stock$459K$15K$499K$529K$535K
Retained Earnings-$151M-$25M-$84M-$123M-$160M
Accumulated OCI-$461K-$2M-$321K$6K$5K
Total Stockholders Equity$12M-$26M$86M$59M$29M
Total Liabilities & Equity$18M$6M$92M$66M$56M
— Key Metrics —
Total Debt$0$164K$213K$361K$19M
Net Debt-$4M-$5M-$87M-$33M-$19M
Total Investments$0$0$0$28M$14M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms